MACH Translational Platforms are key vehicles to develop tomorrow’s healthcare, often working in partnership with life science companies to deliver improvements in the prevention, diagnosis, treatment and palliation of ill health. Our platforms rely on their growing capability in transformative digital approaches benefiting both patients and the economy.
They are at the international cutting edge, are sustainable and accessible and often initiate pilot work, with contributions recognised in outputs such as publications and patents.
- The Clinical Trials and Research Facilitation Committee facilitates support to increase capacity for high quality clinical trials across the MACH network.
- Data Driven Healthcare Improvement aims to align aspects of data use and governance across MACH partners. The committee supports and facilitates collaborative activities across community, primary, secondary and tertiary care, and fosters knowledge transfer capability and workforce training using leading methodologies.
- This committee promotes engagement and funding opportunities for Health Services Improvement and Implementation research across MACH, including the community, primary, secondary and tertiary care sectors.
- The MACH Omics group aims to consolidate the precinct as a multi-omics leader and precision medicine hub covering: epigenomics, genomics, metabolomics, microbiomics, lipidomics, proteomics and transcriptomics.
- The role of the Molecular Imaging Committee is to facilitate support to increase capability and capacity of medical imaging for research. The committee will identify the key priorities and implement strategies to achieve these.
- The committee is underpinned by Translational Platforms to develop Tomorrow’s Healthcare as articulated in the MACH Strategy 2020 to 2025 which include: Note: This is not an exhaustive list and further Translational Platforms may be established based on need and opportunity.